Gilead combo treatments for HCV perform well in Phase II

Gilead Sciences' (GILD) oral combination therapy of Sofosbuvir and Ledipasvi cleared chronic hepatitis C virus in 64-100% of patients in a Phase II trial called Electron2. The combo was tested with and without Ribavirin.

In another study of Sofosbuvir and GS-5816, the cure rate was 94.8-96.1%. (PR)

See more on Hepatitis C drug studies.

From other sites
Comments (4)
  • tipper 1
    , contributor
    Comments (329) | Send Message
    I bet Waxman would sign up for a GILD treatment if needed.
    10 Apr 2014, 09:01 AM Reply Like
  • MineMan
    , contributor
    Comments (601) | Send Message
    Am I missing the part where the GILD treatment immunizes patients against re-infection? Like the SGMO HIV therapeutic does.
    Methods used to create the HIV treatment is also able to create immunity for other viruses, including HCV,HPV, HEP a,b,c, etc, also Herpes Virus.
    10 Apr 2014, 09:55 AM Reply Like
  • johnch789
    , contributor
    Comments (47) | Send Message
    there is NO immunization drug for HCV ... have had many patients re infect post successful completion of HCV treatment ....standard of care for 1a genotype remains with interferon and sofosbuvir and "riba" ... in dec of this year the standard of care will be all oral meds for genotype 1a .... other genotypes are easier to treat .... it is a huge cash cow for the company that does all oral combo for 1a ..... abbvie is the one to watch

    10 Apr 2014, 12:48 PM Reply Like
  • GaryLee276
    , contributor
    Comments (151) | Send Message
    What does 64-100% mean?
    11 Apr 2014, 12:59 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs